Plain answers
The questions people actually ask - answered in plain English, with links to check the facts yourself. Nothing here is medical advice.
On July 23-24, 2026, an FDA advisory committee reviews seven peptides and votes a recommendation on whether licensed pharmacies should be allowed to compound them. That vote is advisory and non-binding - a recommendation, not a final rule. See exactly where each one stands on the tracker.
Most are not FDA-approved drugs and have no cleared legal pathway for compounding, so they aren't lawfully sold for human use. That's why online sellers label them "research use only / not for human consumption" - a workaround the FDA has targeted in warning letters. Legality is precisely what this review is about.
It's documented. Independent testing of falsified peptide products has found purity ranging from roughly 5% to 75%, plus arsenic and lead above injectable-drug limits, and the FDA has reported hospitalizations from dosing errors with unregulated injectable product. The danger isn't the molecule in the abstract - it's not knowing what's actually in the vial. See the sourced figures in By the Numbers and how to stay safe in Safety.
Not exactly. The review is about whether pharmacies may legally compound these substances — building a legal, regulated pathway, not adding a new prohibition. Today most already have no cleared legal channel. Follow the status on the tracker.
Not exactly. The review is about whether pharmacies may legally compound these substances - building a legal, regulated pathway, not adding a new prohibition. Today most already have no cleared legal channel. Follow the status on the tracker.
A licensed compounding pharmacy is inspected, dispenses against a prescription, and must meet identity, potency and sterility standards. An anonymous online seller does none of that. Telling them apart — and reporting the illegal ones — is covered step by step in Safety & the Grey Market.
A licensed compounding pharmacy is inspected, dispenses against a prescription, and must meet identity, potency and sterility standards. An anonymous online seller does none of that. Telling them apart - and reporting the illegal ones - is covered step by step in Safety & the Grey Market.
No. The vote is only a recommendation. Real access would change only if the FDA later opens a formal rulemaking — which is also the stage with a public comment window where an ordinary person’s input carries legal weight. How the process works →
No. The vote is only a recommendation. Real access would change only if the FDA later opens a formal rulemaking - which is also the stage with a public comment window where an ordinary person's input carries legal weight. How the process works →
The comment that carries the most weight comes later, if the FDA opens a formal rulemaking - and yes, it matters: in rulemaking the agency must respond to substantive comments. Agencies weigh the substance of comments, not the volume of identical form letters, so a specific, personal comment counts far more than a copy-paste. We'll tell you the moment the window opens. Get notified →
Report it to the FDA's MedWatch program - it's how safety signals get on the record. We walk through exactly how (and how to report an illegal seller) in Safety.
No. Peppies does not sell, promote, or facilitate the sale of any peptide, and makes no money from their sale. It's an independent education and advocacy resource. Read our full position on the About page.
No. Peppies is an independent private venture, not affiliated with, endorsed by, or acting on behalf of the FDA or any government body.
Peppies was founded by an entrepreneur with a track record of turning confusing consumer problems into organized public action. We don’t sell peptides, and we’re transparent about the incentive: we’d benefit only from a legal, regulated market — the same outcome that makes people safer — not from today’s grey market. Full disclosure is here.
Peppies was founded by an entrepreneur with a track record of turning confusing consumer problems into organized public action. We don't sell peptides, and we're transparent about the incentive: we'd benefit only from a legal, regulated market - the same outcome that makes people safer - not from today's grey market. Full disclosure is here.
Get notified
The vote is advisory. The decision that shapes access comes later - if and when the FDA opens a formal public comment window. Most people never hear it opened. Join the list and we'll tell you the instant it does, with step-by-step instructions to file a comment that counts.
